FDA approves first pill for postpartum depression

The Food and Drug Administration last week approved Zurzuvae (zuranolone), the first pill to treat postpartum depression in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider at certain health care facilities. Patients prescribed Zurzuvae will take the drug for 14 days. PPD symptoms can range from sadness and loss of energy to cognitive impairment and suicidal ideation. About one in eight women experience PPD symptoms, and the rate of depression diagnoses at delivery is increasing, according to the Centers for Disease Control and Prevention. The American Hospital Association recently released an infographic highlighting how hospitals can help support maternal mental health. (FDA news release, 8/4/23)